Bessemer Group’s Entera Bio ENTX Stock Holding History

Bessemer Group’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-140,843	Closed	-$270K	–	2568
2025 Q3	$270K	Hold	140,843	–	–	﹤0.01%	1050
2025 Q2	$268K	Buy	+140,843	New	+$278K	﹤0.01%	1025

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bessemer Group's ENTX Position: Q4 2025 in Review

Bessemer Group sold out of Entera Bio (ENTX) in Q4 2025, closing a stake of 140,843 shares — an estimated $270K sold.

Bessemer Group first reported a position in ENTX in Q2 2025 and held it in 2 quarters. The position peaked at $270K in Q3 2025. 22 funds tracked by Wall St. Rank hold ENTX as of Q4 2025.

Bessemer Group reported no remaining Entera Bio position as of Q4 2025 after selling out during the quarter.
Bessemer Group sold 140,843 Entera Bio shares in Q4 2025, an estimated $270K.
Bessemer Group first reported a position in Entera Bio in Q2 2025 and held it in 2 quarters.
Bessemer Group's Entera Bio position peaked at $270K in Q3 2025.
22 funds tracked by Wall St. Rank held Entera Bio as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.